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Reserpine profoundly inhibits delayed hypersensitivity responses in a  variety 
of experimental systems (1-9).  Schnyder and Storck (1) initially proposed that 
reserpine suppressed contact sensitivity (CS) 1 through an autonomic or central 
nervous system effect which  interfered with the afferent limb of the immune 
response. This view was consistent with the best-known pharmacological property 
of the drug, depletion of stores of catecholamines and serotonin (5-hydroxytryp- 
tamine) (5-HT) in the brain and other sites, but was not supported by subsequent 
work of other investigators. For example, Polak and Turk reported that reserpine 
did  not  alter  the  afferent limb  of CS  (3).  They  found instead  that  the  drug 
suppressed  the efferent limb of the response, an effect they thought might be 
due to peripheral  vasoconstriction and diminished vascular permeability.  Ger- 
shon et al.  (4) and Askenase et al. (5) confirmed that reserpine interfered with 
cellular immunity by blocking expression of the efferent limb of the response, 
but suggested yet another mechanism to account for this effect. They proposed 
that elicitation of delayed hypersensitivity (DH) reactions required the T  cell- 
directed release of 5-HT from mast cells at the site of antigenic challenge, and 
that reserpine  interrupted  this sequence by depleting mast cell granules of 5- 
HT. 
This hypothesis accommodated a  variety of experimental findings (4-9),  but 
is  difficult to  reconcile  with  several  more  recent observations.  At  least  four 
different groups have reported that DH responses can be expressed in the virtual 
absence of tissue mast ceils. Three of these groups found that W/W  v (10-13) or 
S1/S1 d (12,  13)  mice, whose tissues contain <1%  the normal numbers of mast 
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ceils (14,  15), and which cannot express detectable passive cutaneous anaphylaxis 
(10,  16),  nevertheless  developed  DH  responses  whose  intensity  equalled  or 
exceeded those in littermate control mice with normal numbers of mast cells. A 
fourth group also confirmed the occurrence of DH responses in W/W v and S1/ 
S1 d mice, although in these experiments DH was associated with less swelling in 
mast cell-deficient mice than in littermate controls (16). Furthermore, reserpine 
blocked the  swelling (12,  16) and  the  leukocyte infiltration  (12) associated with 
delayed  hypersensitivity  responses  in  mast cell-deficient  mice,  suggesting  that 
the drug's ability to abrogate DH may be independent of its effect on mast cells. 
These observations prompted us to reevaluate the mechanism by which reser- 
pine interferes with the expression of cellular immunity. We now report evidence 
for a  previously unrecognized  action  of reserpine  that can explain its ability to 
block expression of cellular immunity either in the presence or in the absence of 
tissue mast cells: the inhibition of effector T  cell function. 
Materials and  Methods 
Mice.  Female  BALB/c,  C57BL/6J,  and  mast  cell-deficient  mice  (WB/ReJ-W/+  × 
C57BL/6J-WV/+)F1 (W/W v,  +/+)  were  purchased  from The Jackson  Laboratory (Bar 
Harbor, ME). All mice were used at 6-10 wk of age. 
Reagents.  2,4-Dinitro-l-fluorobenzene (DNFB) was obtained from Eastman Kodak Co. 
(Rochester, NY). 4-Ethoxymethylene-2-phenyl oxazalone (Ox) was purchased from BDH 
Chemicals  Ltd.  (Poole,  England).  Reserpine  USP  solution  (serpasil  2.5  mg/ml),  was 
purchased from CIBA Pharmaceutical Co. (Summit, NJ). 
Elicitation and  Quantitation of Contact Sensitivity Response.  Mice  were  sensitized  to 
DNFB by applying 25 #1 of 0.5% DNFB in acetone/olive oil (4:1 by volume) to the shaved 
abdomen on days 0 and  1. Mice were sensitized to Ox by applying 50 #1 of 3.0% Ox in 
acetone/olive oil (4:1 by volume) to the shaved abdomen on days 0 and 1. Unless otherwise 
specified, contact sensitivity reactions were elicited by challenging mice on both sides of 
the left ear with 20 •l  of either 0.2% DNFB or 0.5% Ox (10 #1 to each side of the ear, 5 
d after sensitization) in a vehicle of 4:1 acetone/olive oil. The right (control) ear received 
acetone/olive oil alone. 
The effect of systemic administration of reserpine on the expression of contact sensitiv- 
ity was demonstrated by administering the drug (5 mg/kg, i.p.) 18 h before ear challenge 
(4,  12). Control animals were injected with 0.9% NaCI alone. 
The contact responses were measured by an ear swelling assay. In most experiments, 
the reactions were also quantitated by determining ear weight ratios and by a radiometric 
assay of leukocyte migration.  (a) Ear swelling:  the  mice were lightly anesthetized  with 
ether and the thickness of the ears was measured immediately before challenge and 24 h 
after challenge with a  Mitutoyo engineer's micrometer (13,  17). The increment (A) of 
swelling (24 h value -  baseline value) was expressed in units of 10  -4 inches. (b) Ear weight 
ratio: mice were killed by cervical dislocation 24 h after challenge; the ears were cut off 
at the hairline and trimmed carefully so that each ear was a mirror image of the other. 
The contact response of each mouse was expressed as the ratio of the weight of the left 
(challenged)  ear and right (control) ear (12,  13).  A  few transfer experiments required 
challenging both ears with antigen.  In these experiments, the results were recorded as 
the  actual  weights  of the  ears  in  each  experimental  group.  (c)  Radiometric  assay  of 
leukocyte emigration: immediately after challenge, mice were injected intraperitoneally 
with 0. I  ml of 10 -7 M 5-fluoro-2-deoxyuridine (FUDR) and, after an additional 30 min, 
with 2 #Ci of 125I-5-iodo-2-deoxyuridine Q~sI-IUDR) sp act, 2,200 Ci/mmol; (New England 
Nuclear,  Boston,  MA  [18,  19]).  The  ears  were amputated,  trimmed,  and  weighed  as 
described above and then were washed to deplete the tissue of free 125I-labeled species as 
previously described (12,  13). The radioactivity remaining in the washed ears was counted 
in a gamma counter (No.  1185;  Tracor Analytic, Inc., Elk Grove Village, IL). The CS MEKORI  ET  AL.  1937 
response of of each mouse was expressed as the ratio of counts per minute of challenged 
to that of control ears according to the formula: (cpm left ear -  background)/(cpm right 
ear -  background). For all three assays, the results are expressed as mean +  SE. 
Antigen-induced Proliferation of Immune Lymph Node Cells (I-LNC) In Vitro.  Mice were 
sensitized  with  Ox  as  described  above.  On  day  5,  the  axillary,  brachial,  mandibular, 
popliteal,  and  inguinal  lymph  nodes  of the  sensitized  mice  were  removed aseptically, 
teased over a  metal screen in RPMI  1640 medium (Gibco, Grand Island, NY) at 20°C, 
and then washed twice with RPMI medium. The cells [I-LNC(Ox)] were then resuspended 
(1.0 X  10 6 cells/ml) in RPMI-FCS (RPMI medium supplemented with glutamine [0.3 rag/ 
ml], 2-mercaptoethanol [2.5 ×  10  -3 M], gentamycin [10 #g/ml], and 10% fetal calf serum 
[M. A. Bioproducts, Walkersville, MD). The cells were then distributed into 96-well flat- 
bottomed tissue culture plates (Tissue Culture Cluster; Costar, Cambridge, MA) at 2.0 × 
105 cells (in 200 #1 RPMI-FCS) per well. 
[3H]Thymidine [SH]TdR incorporation was used as a measure of lymphocyte prolifer- 
ation. To augment lymphocyte proliferation,  some wells received antigen (Ox3s-human 
serum albumin [Ox38-HSA], prepared according to the method of Yoshimura and Cinader 
[20]) given in 200 #1 of RPMI-FCS to achieve the final concentrations indicated in Results. 
Some wells also received reserpine (in 5 ~1 of RMPI-FCS) to achieve the final concentra- 
tions indicated in Results. The cells were then placed in a humidified atmosphere of 5% 
CO2/95% air at 37°C for 3 d. [SH]TdR (6.7 Ci/mmol; New England Nuclear) was then 
added (1  uCi/well) for an additional  24 h. The cells were then harvested onto glass fiber 
filters  (No.  23-994;  M.  A.  Bioproducts),  the  filters  placed  in  Aquasol  (New  England 
Nuclear), and the disintegrations  per minute of incorporated [~H]TdR was measured in 
a Tacor Mark IV 13 counter. 
Transfer  of Contact Sensitivity.  DNFB-immune lymph node cells I-LNC(DNFB) were 
obtained from donor mice sensitized on days 0 and 1 with a total of 55 #1 of 0.5% DNFB 
in 4:1 acetone/olive oil (25 gl applied to the shaved abdomen, and 5 gl to each of the feet 
and ears). I-LNC(Ox) were obtained from donor mice sensitized with a total of 80 #1 3% 
Ox in 4:1 acetone/olive oil (50 ~1 to the abdomen, and 5 tA to each of the feet and ears). 
On day 4  (for  DNFB) or day 5  (for Ox) the draining  lymph nodes were removed and 
single-cell  suspensions  were  prepared  and  washed  in  RPMI  medium.  Recipients  were 
given 5 ×  107 I-LNC intravenously. Mice were ear challenged within  1 h of transfer unless 
otherwise specified. For cotransfer experiments I-LNC from two different donor groups 
(5  ×  10  v of each type of I-LNC) were mixed and  injected intravenously into the same 
mouse. 
In Vitro Treatment of I-LNC with Reserpine to Block Transfer of Contact Sensitivity.  I-LNC 
prepared as above were diluted to a concentration of 5 ×  106 cells/ml in RPMI medium, 
pH 7.2, supplemented with 5% FCS. Reserpine was added in various final concentrations 
(as indicated in Results) and the reaction was allowed to proceed for 60 min at 37°C in a 
humidifed atmosphere of 5% CO2, 95% air. Control I-LNC were incubated in the same 
manner  but  without  the  addition  of reserpine.  Viability  of cells  at  the  end  of each 
incubation  (with  or without  reserpine)  was assessed  by trypan  blue  exclusion  and  was 
found to be >90% in all experiments.  The reserpine-treated or untreated cells were then 
concentrated by centrifugation, resuspended in fresh RPMI medium, counted, and then 
immediately transferred  intravenously or intradermally  into naive mice.  Generally, the 
ears were challenged for CS within  1 h of passive transfer of the I-LNC. 
Quantitation of Reserpine-induced Inhibition of Contact Sensitivity.  For measurements of 
ear swelling,  percent  inhibition  of the  contact response was calculated as:  [(swelling  in 
mice given control I-LNC) -  (swelling in mice given reserpine-treated  I-LNC)/(swelling 
in  mice  given  control  I-LNC)]  ×  100.  For  ear  weight  or  125I-IUDR  ratios,  percent 
inhibition of the contact response was calculated as: [(ratio of mice given control I-LNC 
-  1.0) -  (ratio of mice given reserpine-treated I-LNC -  1.0)/(ratio of mice given control 
I-LNC-  1.0)] ×  100. 
125I-IUDR Incorporation by Spleen, Lymph Node, or Bone Marrow Cells In Vivo.  12~I-IUDR 
is incorporated into all rapidly dividing cells, including those in the spleen, lymph nodes, 
and bone marrow (21). In assays of DH, ratios of ~zsI-IU DR cpm in challenged and control 1938  RESERPINE-INDUCED  INHIBITION  OF  CONTACT  SENSITIVITY 
ears primarily reflect differences in  125I-labeled leukocytic infiltration (12,  18). Further- 
more, histological analyses indicate that most of the leukocytes which infiltrate CS reactions 
are bone  marrow  derived (i.e., granulocytes and  monocytes  [12  I8]).  If, for whatever 
reason,  125I-IUDR  incorporation  by  bone  marrow  cells  is  affected  by  the  reserpine 
treatment, then the ~25I-IUDR ratios obtained in these mice might be altered artifactually. 
In some experiments, we therefore removed one femur from each mouse at the time of 
sacrifice, trimmed the femurs of soft tissue, washed them three times in ethanol (13,  18), 
and then determined their radioactivity in a gamma counter as described above. In these 
experiments we also determined incorporation of 125I-IUDR  by spleen or lymph node 
cells. The spleens and axillary lymph nodes were removed at the time of sacrifice, minced, 
washed three times in ethanol, and their radioactivity measured in a gamma counter. 
Measurement of Histamine and Serotonin.  Duplicate aliquots of I-LNC (5.0 ×  106 cells 
per determination) were assayed for histamine content fluorometrically with an Autoan- 
alyzer II (Technicon Instruments Corp., Tarrytown, NY) equipped to detect histamine in 
the 0.5-10  ng/ml range (22).  Duplicate aliquots of I-LNC (5.0 ×  106 cells per determi- 
nation) were  assayed for serotonin  (5-HT)  content  by the  highly sensitive and  specific 
enzymatic-isotopic method  of Hammel et al. (23),  in which  5-HT  is converted to [3H]- 
melatonin in a  two-step reaction (23).  The relationship of dpm to 5-HT is linear in the 
0.5-10 ng range (23). Internal standards of histamine or 5-HT (both from Sigma Chemical 
Co., St. Louis, MO) were used in each assay (22, 23). 
Statistical Analysis.  The  results  of ear  swelling assays,  measurements  of actual  ear 
weights, and determinations of a2~I-IUDR incorporation into spleen, lymph node, or bone 
marrow cells, were compared for statistical significance (P <  0.05) using Student's t test 
(two-tailed). The Mann-Whitney U  test (two-tailed) was used to evaluate the significance 
(P <  0.05) of differences in measures of CS based on ratios between the left (challenged) 
and right (control) ears. 
Results 
Systemic  Treatment  with  Reserpine  Blocks  Expression  of Contact  Sensitivity  and 
Incorporation  of 125I-IUDR into Lymph Node Cells.  As described by Gershon  et 
al.  (4),  reserpine  given  intraperitoneally  (5  mg/kg)  18  h  before  challenge  for 
contact  sensitivity virtually abolished  the  animal's  ability to  develop  a  CS  re- 
sponse,  whether judged  by measures  of tissue swelling or  125I-labeled leukocyte 
emigration  (Table  I).  At  this  dose,  the  drug  also  produced  other  remarkable 
TABLE  I 
Systemic Treatment with Reserpine Ablates Contact Sensitivity Responses and Inhibits LNC 
Proliferation 
Contact sensitivity responses  Incorporation  of 12~I-IUDR 
Reserpine 
Group  treatment  Ear weight  Ear I~I-IUDR  Bone marrow 
ratio (L/R)  ratio (L/R)  cells  Spleen cells  Lymph node cells 
A  -  2.22 ±  0.06  7.04 +  0.45  2,752 +  201  15,182 +  1,512  1,311  ±  134 
B  +  1.04±0.04  1.00+0.06  2,453±585  16,033±2,081  224±38 
P  .< 0.01  vs. A  P  <  0.008 vs. A  NS vs. A  NS vs. A  P  <  0.02 vs. A 
BALB/c mice were sensitized by epicutaneous application of oxazolone on days 0 and  1. Group B 
received reserpine (5 mg/kg, i.p.)  18 b before challenge of the left ear (L) with oxazolone on day 5. 
The right ear (R) received vehicle alone and served as a control. Mice in group A were injected with 
0.9%  NaCI instead of reserpine. FUDR and ~251-1UDR (2 uCi/mouse, i.p.) were administered within 
30  rain  of ear  challenge  with  antigen.  24  b  contact  sensitivity reactions were  quantitated  by 
t25,  determining the weight ratios and  I-IUDR ratios of challenged and control ears. The t~sI-IUDR 
incorporation of femoral bone marrow cells, spleen cells, and lymph node cells was also determined. 
The results are shown as tbe mean + SE, and were tested for statistical significance by the two-tailed 
Mann-Whitney U test or two-tailed Student's t test as described in the text. NS, not significant (P > 
O.O5). MEKORI  ET  AL.  1939 
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F[GURr  1.  Reserpine inhibits baseline and antigen-augmented  levels of [3H]TdR incorpora- 
tion by LLNC(Ox) in vitro. 1-LNC(Ox) were recovered from C57BL/6J mice that had been 
sensitized to Ox  5 d previously. The I-LNC(Ox) were incubated  with or without  specific 
antigen (Ox~s-HSA) for 3 d, at which time [SH]TdR was added for the final day of culture. 
Some populations also were treated with reserpine,  which was given at the time of antigenic 
challenge and every 24 h thereafter. The addition of specific antigen significantly augmented 
[~H]TdR incorporation  by I-LNC not exposed to reserpine  (P <  0.005, <0.001, or <0.001 
when results with 10, 100, or 200 ,g Ox3s-HSA/ml were compared with results with no added 
antigen by two-tailed Student's t test). Reserpine markedly diminished [~H]TdR incorporation 
at all concentrations tested (P < 0.001 when results with any dose of reserpine were compared 
to results in the absence of the drug at any concentration  of antigen (0, 10, 100, or 200 gg/ 
ml) by two-tailed Student's  t test). 
systemic  effects.  For  example,  mice  treated  with  reserpine  rapidly  (within  30 
rain)  developed profound  depression  of central  nervous  system function:  they 
responded  weakly  or  not  at  all  to  touch,  and  neither  ate  nor  drank  for  the 
remainder of the experiment (-42  h).  Moreover, reserpine appeared to inhibit 
lymphocyte incorporation of 125I-IUDR, as judged by measuring the radioactivity 
of axillary lymph nodes at the  time of sacrifice (42  h  after reserpine  and  24 h 
after 125I-IUDR). In contrast to reserpine's striking effect on LNC incorporation 
of 125I-IUDR (Table  I),  incorporation  of the  isotope by bone  marrow cells or 
spleen cells was not affected by the drug. 
Reserpine Inhibits Lymphocyte Incorporation of [3H]TdR In  Vitro.  Because  of 
experiments  such  as that  shown  in  Table I, and  because of reports  suggesting 
that  reserpine  may have antiproliferative  effects in  other  systems (24,  25),  we 
tested the effect of the drug on [3H]TdR incorporation by I-LNC in vitro. 
We first administered  the  drug  to  I-LNC 30  rain before the  introduction  of 
specific antigen  (Ox), and at daily intervals thereafter (total of four administra- 
tions).  The  result  is  shown  in  Fig.  1.  Reserpine  nearly  eliminated  [~H]TdR 
incorporation by I-LNC incubated without Ox-HSA, and also markedly reduced 
the augmented levels of isotope incorporation exhibited by cells stimulated with 1940  RESERPINE-INDUCED  INHIBITION  OF  CONTACT  SENSITIVITY 
additional  specific antigen  in  vitro.  At the concentrations  tested, reserpine had 
no effect on lymphocyte viability (viability of cells on day 4 was always >90% by 
trypan  blue exclusion).  Additional  similar  experiments  (data  not shown) dem- 
onstrated  that reserpine  largely blocked (>90%  inhibition)  baseline or antigen- 
stimulated [~H]TdR incorporation  by I-LNC derived from BALB/c or (C57BL/ 
6J x  A/J)F~  mice at doses as low as 0.25  •g/ml  (0.4 ~M),  when added  to the 
cultures  on  a  daily  basis,  and  at  doses  as  low  as  2.5  ug/ml  (4  ~M)  when 
administered only once at the beginning of culture,  30 min before the addition 
of antigen. 
Gershon et al. (4) suggested that reserpine abrogated the expression of T  cell- 
dependent  responses  indirectly,  by  depleting  stores  of  5-HT  in  mast  cells. 
Examination of our BALB/c I-LNC preparations after toluidine blue or Wright's 
staining  showed  that  they  did  contain  a  few  mast  ceils  (<0.1%).  They  also 
contained detectable amounts of 5-HT (84 ng per 1.0 X  10 6 cells). We therefore 
decided  to  rule  out  the  possibility  that  reserpine's  ability  to  inhibit  I-LNC 
proliferation  in  vitro was mediated  indirectly,  by an effect of the drug on this 
minor population of mast cells. We prepared I-LNC(Ox) from W/W  v mice whose 
tissues contained <1% the number of mast cells of their littermate controls (14), 
and from similarly sensitized tittermate control (+/+) mice with normal numbers 
of mast  cells.  W/W  v I-LNC preparations  contained  no  mast  cells by toluidine 
blue or Giemsa staining.  In addition, these preparations contained no detectable 
histamine  (<0.5  ng per  1.0 ×  106 cells) or 5-HT (<0.5 ng per  1.0 x  10 6 cells). 
By contrast,  rare  mast cells (<0.1%) were present in  +/+  I-LNC preparations, 
and these populations  contained detectable amounts of both histamine  (6.6 ng 
per 1.0 x  10 6 cells) and 5-HT (57 ng per  1.0 X  10 6 cells). As shown in Fig. 2, a 
single administration  of reserpine (4 #M) at the beginning of culture markedly 
inhibited  both  baseline  and  antigen-augmented  [SH]TdR  incorporation  by  I- 
LNC  derived  from  W/W  v or  +/+  mice.  This  result  indicates  that  reserpine's 
effect on lymphocyte [SH]TdR incorporation  does not require the intervention 
of mast cells. 
Reserpine  Treatment of I-LNC In Vitro Blocks Their Ability  to Transfer CS.  The 
T  cells that proliferate in vitro when restimulated with specific antigen represent 
a different population than  the T  cells capable of passively transferring  contact 
sensitivity (26).  Furthermore,  Gershon  et al.  (4) found that  lymphocytes from 
mice sensitized  to sheep red  blood cells and  treated  with reserpine  8  h  before 
sacrifice were as effective in passively transferring DH reactivity as were lympbo- 
cytes from sensitized mice not treated with the drug. This result was interpreted 
as evidence that the significant effect of reserpine was "on cells of the host, not 
on  the  immunocompetent  cells of the donor"  (4).  However, standard  transfer 
studies  use sensitized  lymphocytes that  are  washed  before injection  into naive 
recipients, and  our studies of I-LNC [SH]TdR incorporation  in vitro indicated 
that the effects of reserpine on lymphocyte proliferation were partially reversible 
(data  not shown).  We therefore determined  whether  reserpine  could interfere 
with  the  function  of effector cells that  transfer  CS,  using an  approach  which 
avoided washing of the treated cells. 
In  the  first  series  of  experiments,  immune  lymph  node  cells  from  mice 
sensitized to oxazolone I-LNC(Ox) were incubated for 1 h at 37°C with different MEKORI  ET  AL.  1941 
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FIGURE 2.  Reserpine inhibits baseline and antigen-augmented levels of [3H]TdR incorpora- 
tion by I-LNC(Ox) independently of an effect on mast cells. The experiment was similar to 
that shown in Fig.  1,  except  that 1-LNC(Ox)  were derived from mast cell-deficient W/W  v 
mice or from littermate control (+/+) mice with normal numbers of mast cells. Reserpine (4 
#M) was administered once at the beginning of culture, and 24-h [SH]TdR incorporation was 
determined  3  d  later.  Specific antigen (100  #g/ml) augmented  [SHITdR  incorporation by 
W/W  v or +/+ I-LNC (P <  0.001 compared to corresponding results without antigen, by two- 
tailed Student's t test). Reserpine virtually eliminated [~HITdR incorporation by W/W  v or +/ 
+  I-LNC at all concentrations of antigen (0,  10, or 100 #g/ml) tested (P <  0.001 by two-tailed 
Student's t test). 
concentrations  of reserpine.  The  cells were  then  centrifuged,  resuspended  in 
fresh  RPMI medium,  and  immediately injected intravenously into each of five 
syngeneic  recipients  (5.0  ×  107  cells  per  mouse).  Control  cells  included  I- 
LNC(Ox) not treated with reserpine, and lymph node cells recovered from mice 
not sensitized to Ox (naive lymph node cells, N-LNC). These populations were 
incubated, resuspended, and injected in the same manner as reserpine-treated I- 
LNC(Ox).  Recipient  animals  were  challenged  within  1  h  of cell  transfer  by 
applying antigen  to the left ear, and the contact responses were measured 24 h 
later. 
At a concentration of 25 #g per 1.0 ×  106 cells/ml (40 #M), reserpine treatment 
produced  64%  inhibition  of  the  contact  response  according  to  micrometer 
measurements  of ear swelling,  100%  inhibition  according to ear weight ratios, 
and  96%  inhibition  according  to  ]25I-IUDR ratios  (experiment  1,  Table II).  It 
should be pointed out that the contact responses elicited with reserpine-treated 
I-LNC(Ox) were even smaller than  those elicited in mice which received naive- 
LNC, as judged by the results of micrometer measurements or ear weight ratios. 
When the data are viewed in this fashion (i.e., after subtraction of the nonspecific 
responses  elicited  in  mice  that  received  N-LNC),  it  is  evident  that  reserpine 
treatment of I-LNC in vitro completely abolished the transfer of CS. 
In experiment  2 (Table II),  we tested the effect of treating  I-LNC(Ox) with 
20 #M reserpine (12.5 #g reserpine per 5.0 ×  10 6 cells/ml). Since 5.0 ×  10 7 LNC 
were  transferred  to  each  mouse,  animals  in  the  reserpine  treatment  group 
received  I-LNC  that  had  been  incubated  with  a  total  of 125  #g of reserpine. 1942  RESERPINE-INDUCED  INHIBITION OF  CONTACT  SENSITIVITY 
TABLE II 
Reserpine Treatment of I-LNC Abrogates Their Ability to Transfer Contact Sensitivity 
Contact Sensitivity Responses 
Donor  Reserpine  Left ear 
Exp,  cells  treatment  swelling  p  Ear weight  p  Ear 12Sl-IUDR 
(A X  10  -4  ratio (L/R)  ratio (L/R) 
inches) 
A,  I-LNC(Ox)  --  61  ±  6  1.38 ±  0.04  3.09 ±  0.28 
B.  I-LNC(Ox)  25 #g/ml  13 ±  6  <0.001  vs. A  1.00 ±  0.02  <0.004 vs. A  1.07 ±  0.11  <0.004 vs. A 
C.  Naive-LNC  --  18±2  <0.001vs.  A,  1.08±0.02  <0.004vs.  A,  1.07±0.11  <0.004vs.  A, 
NS vs. B  NS vs. B  NS vs. B 
A.  I-LNC(Ox)  --  53 ±  6  1.56 ±  0.07  3.43 -  0.32 
B.  I-LNC(Ox)  12.5#g/ml  18±2  <0.O01vs.  A  1.09±0.02  <0.01vs.  A  1.07±0.03  <0.01vs.  A 
C.  Naive-LNC  --  14 ±  2  <0.0Ol  vs. A,  1.08 ±  0.02  <0.01  vs. A,  1.08 ±  0.20  <0.01  vs, A, 
NS vs. B  NS vs. B  NS vs. B 
I-LNC(Ox) were recovered from BALB/c mice sensitized to Ox 5 d previously. N-LNC were from 
BALB/c mice not sensitized to Ox. The I-LNC(Ox) were incubated with or without reserpine for 1 
h at 37°C before adoptive transfer into naive BALB/c recipients (see text for further details). Mice 
were challenged on the left ear with Ox, and on the right (control) ear with vehicle alone, within 1 
h of cell transfer.  Mice then received FUDR and~25I-IUDR  intraperitoneally, and the magnitude of 
the CS reactions was determined 24 h later. NS, not significant (P > 0.05). 
This is exactly the same amount of drug that would be administered to a  25  g 
mouse treated with reserpine systemically at 5 mg/kg, the dose used by Gershon 
et al. (4) and in Table I, above. But the reserpine-treated I-LNC were centrifuged 
and  resuspended  in  reserpine-free  medium  before  transfer;  as  a  result,  the 
amount of drug transferred  with the  cells must have been  much less than  125 
~g.  Indeed,  mice that  received  the  reserpine-treated  cells exhibited  only  mild 
sedation,  moved about spontaneously,  and ate and drank.  Yet the  CS reactions 
elicited in these mice were indistinguishable  from the  immunologically nonspe- 
cific reactions  to  Ox  observed in  mice that  received  N-LNC.  Treatment  of I- 
LNC with lower concentrations of the drug (2.5 or 0.5 #g/ml) produced little or 
no inhibition of the CS response (data not shown). 
Reserpine Blocks Transfer of CS Independently of an Effect on Mast Cells.  Gershon 
et al.  (4) proposed that the  abrogation  of CS by reserpine  reflected the  drug's 
ability  to  deplete  mast  cell  stores  of  5-HT.  One  could  therefore  argue  that 
reserpine-treated I-LNC simply transferred sufficient drug to impair the function 
of tissue mast cells at the site of antigen challenge in the recipient mice. To test 
this possibility, we performed an experiment in which  I-LNC(Ox) derived from 
mast cell-deficient  W/W v mice were transfered  into naive W/W v mice. W/W v 
mouse I-LNC(Ox) contained no mast cells by toluidine blue or Wright's staining, 
and contained  undetectable amounts of histamine (<0.5  ng per  1.0  x  106  cells) 
or 5-HT (<0.5 ng per 1.0 x  106 cells). Nevertheless, the W/W V  I-LNC were fully 
competent to transfer CS to W/W v recipients, and treatment of the I-LNC with 
reserpine (20 #M) for 1 h completely inhibited the ability of these cells to transfer 
CS  reactivity  (Fig.  3).  This  experiment  indicated  that  W/W ~ mice  represent 
suitable  donors  and  recipients  for  the  transfer  of CS.  In  addition,  reserpine 
blocked the transfer of CS under conditions where both the I-LNC preparations 
and  the  naive recipient  mice were  essentially  devoid  of mast cells.  This  result MEKORI  ET  AL. 
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FIGURE 3.  Reserpine blocks transfer of CS in W/W  v mice. The experiment was similar to 
those shown in Table II, except that mast cell-deficient W/W" mice were used both as a source 
of I-LNC(Ox) and as recipients  for the transfer of CS.  Recipient  mice received either I- 
LNC(Ox) (group A), I-LNC(Ox) exposed to reserpine (20 #M) for 1 b in vitro (group B), or, 
as a control, I-LNC derived from W/W" mice sensitized to the unrelated antigen DNFB (group 
C). (*) Reserpine,  12.5 #g per 5 x  106 ceUs/ml for 1 h. Mice were challenged with antigen 
(left ears) or vehicle (right ears) within 1 h of cell transfer, and the intensity of the CS reaction 
was determined 24 h later (see text for details). W/W  v  mice that received I-LNC(Ox) developed 
CS  reactions  (group  A).  By contrast,  W/W  v mice that  received  I-LNC(Ox)  treated  with 
reserpine (group B) exhibited  reactivity to Ox which was statistically indistinguishable from 
that seen in mice which received I-LNC from animals sensitized to an unrelated antigen (group 
C). 
strongly suggests  that  reserpine  blocks the  transfer of CS  independently  of an 
effect on mast cells. 
We also measured the ]25I-IUDR incorporation into the femoral bone marrow, 
spleen, and axillary lymph nodes of the same recipient W/W v mice depicted  in 
Fig.  3.  In  contrast  to  systemic  treatment  with  reserpine  (5  mg/kg),  which 
profoundly diminished LNC incorporation of 125I-IUDR (Table I), passive trans- 
fer  of reserpine-treated  I-LNC  had  no  effect  on  the  low  levels  of  125I-IUDR 
incorporation  exhibited by the  LNC of the naive recipient mice (the values for 
groups A, B, and C  were 51  ___ 9, 48 __+  10, and  58 +  14 cpm). These groups of 
mice also exhibited little or no differences in the levels of 125I-IUDR incorpora- 
tion by bone marrow cells (the values for groups A, B, and C  were  1,696 _+ 201, 
1,600 +  241, and  1,704 +  36) or spleen cells (the values for groups A, B, and C 
were 2,693  +  159,  2,749 +  276, and 3,504  +  191). 
Reserpine-induced  Suppression of CS  Is  Not  Due  to  Systemic Effects of Drug 
Transferred  with the Treated I-LNC.  Reserpine blocked the transfer of CS by I- 
LNC (a) when  used at concentrations  that produced  only mild sedative effects 
in  recipients  of the  treated  cells,  and  (b) when  mast cell-deficient  W/W v mice 
were used both as the source of I-LNC and as the naive recipients in a  transfer 
experiment.  However, one could still explain these results by postulating that I- 
LNC incubated with reserpine simply transferred sufficient drug to block CS by 
a  systemic action on a  host cell population other than mast cells. 
To test this possibility, we performed an experiment in which 5  ×  10 7 I-LNC 
from mice sensitized to DNFB [I-LNC(DNFB)] were cotransferred with 5  ×  10  7 
reserpine-treated  or untreated  [I-LNC(Ox)] (Fig.  4).  The  left ears of recipient 
mice were then  challenged  with Ox,  while the  right  ears were challenged  with 
DNFB.  Mice that received both reserpine-treated I-LNC(Ox) (12.5 #g reserpine 
per 5.0 ×  106 cells/ml) and untreated  I-LNC(DNFB) (group B) exhibited signifi- 
cant  suppression  of the  response to Ox (73%  suppression by ear swelling  mea- 1944  RESERPINE-INDUCED  INHIBITION  OF  CONTACT  SENSITIVITY 
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FIGURE 4.  The inhibition of transfer of CS by reserpine is specific for the treated cells. Naive 
BALB/c mice received a  mixture of 5.0  X  107  I-LNC(Ox) and  5.0  x  107  I-LNC  (DNFB) 
(group A), a  mixture of 5.0 x  107 I-LNC(Ox) that had been treated with reserpine (20 #M) 
for 1 h in vitro and 5.0 X 107 I-LNC(DNFB) (group B), or 1.0 ×  l0  s lymph node cells obtained 
from normal BALB/c mice (N-LNC, group C). (*) Reserpine, 12.5 #g per 5 x  106 cell/ml, for 
1 h. All mice were challenged within  1 h  of cell transfer by applying Ox to the left ear and 
DNFB  to  the  right ear.  The  CS  reactions were  measured  24  h  later by  determining the 
thickness (ear swelling [x 10  -4] inches) and weight of the challenged left and right ears. Mice 
that received I-LNC(Ox) treated with reserpine (group B) exhibited no more reactivity to Ox 
than did control mice which received naive-LNC (group C), whether judged by the swelling 
or the actual weight of left ears challenged with Ox. But reactivity to DNFB was the same in 
mice that received I-LNC(Ox) treated with reserpine (group B) as in mice which received I- 
LNC(Ox)  not  treated  with  the  drug  (group  A).  This  result  indicates  that  the  reserpine 
transferred  with  the  treated  I-LNC(Ox)  had  no  detectable  effect  on  the  function  of  I- 
LNC(DNFB) transferred into the same mice. 
C 
surements, 99%  suppression  by ear weight measurements). Once again, when 
the  nonspecific response  elicited  in  mice  that  received  N-LNC  (group  C)  is 
considered, one could conclude that reserpine treatment completely inhibited 
the immunological component of the CS response to Ox. By contrast, there was 
no detectable inhibition of the response to the unrelated antigen, DNFB (com- 
pare groups A and B, Fig. 4).  This experiment shows that, whatever host cells 
or mediators might be affected by the small amount of drug transferred with 
reserpine-treated I-LNC, these systemic effects of the drug are not sufficient to 
block transfer of CS. 
Reserpine-induced Suppression of CS Is Not Due to Local Effects of  Drug Transferred 
with the Treated I-LNC.  The results in Fig. 4 do not prove that the critical effect 
of reserpine in blocking CS  is an effect on T  cells.  For example, in mice that 
received reserpine-treated I-LNC(Ox), the local concentrations of the drug may 
have been higher in the Ox-challenged ear (if the reserpine-treated cells migrated 
to that site) than in the contralateral ear challenged with DNFB. According to 
this scenario, host cells  necessary for expression of CS may have been affected 
by the relatively high concentrations of reserpine present in ears challenged with 
Ox. We therefore performed an experiment to determine whether the important 
effect of reserpine  in  blocking transfer of CS  was  its  effect on  the  treated, 
sensitized T  cells, or its effects on other cells at the site of the CS reaction. 
We first evaluated whether reserpine's ability to block expression of CS could 
be demonstrated when the treated I-LNC were injected directly into the ear. 
We found that pretreatment of I-LNC(Ox) with 20 ~M reserpine for 1 h had no 
effect on the viability of the cells, as determined by measurement of their ability MEKOR1  ET  AL.  1945 
TABLE  III 
Reserpine Treatment Blocks Transfer of Contact Sensitivity Even When I-LNC Are Directly 
Injected into the Site of Antigen Challenge 
Donor cells  Challenge  Ear swelling 
(A X  10 -4 
inches) 
Contact sensitivity responses 
P  Ear weight  P 
mg 
A.  I-LNC(Ox)  Ox  25 4- 2  40.3 _  0.6 
B.  I-LNC(Ox)-Res  Ox  11  --- 1  <0.001  vs.A,  35.8---0.5  <0.001  vs.A, 
NS vs. C or D  NS vs. C or D 
C.  I-LNC(Ox)  Vehicle  7 -  1  <0.001  vs. A,  34.7 +  0.8  <0.001  vs. A, 
NS vs. B or D  NS vs. B or D 
D.  I-LNC(Ox)-Res  Vehicle  9 +  1  <0.001  vs. A,  35.5 4- 0.5  <0.001  vs. A, 
NS vs. B or C  NS vs. B or C 
I-LNC(Ox) were recovered from BALB/c mice sensitized to Ox 5 d previously, and were incubated 
with reserpine [I-LNC(Ox)-Res] or without reserpine [I-LNC(Ox)] (20 #M;  12.5 ~g per 5.0 x  106 
cells/ml) for  1 h  at  37°C.  The  cells were then  centrifuged,  resuspended  in  RPMI  medium,  and 
injected intradermally (2.0 x  106 cells in 20 #l/site) into the dorsal surface of the ears of naive BALB/ 
c  recipients. The  ears  were challenged with Ox  (0.2%;  20 #1 to the dorsal  surface only) or with 
vehicle, within  1 h of cell injection. The magnitude of the CS reactions was determined 24 h later. 
NS, not significant (P >  0.05). 
TABLE  IV 
Local lntradermal Injection of Reserpine-treated I-LNC(Ox) Does Not Interfere with the 
Development of CS to DNFB at the Same Site 
Group 
Contact sensitivity responses 
Donor cells  Challenge  (ear swelling, A  X  10  -~t inches) 
Left ear  Right ear  Left ear  Right ear  Left ear  Right ear 
A.  I-LNC(Ox)  I-LNC(Ox)  Ox  DNFB  28 +  2  (P <  0.001  37 4- 3 (P <  0,001 
vs. B or C)  vs. C, NS vs. B) 
B.  I-LNC(Ox)-Res  I-LNC(Ox)-Res  Ox  DNFB  11 +  2  (NS vs. C)  34 +  4  (P <  0.001 
vs. C) 
C.  I-LNC(Ox)  I-LNC(Ox)-Res  Vehicle  Vehicle  I0 +  1  10 ±  1 
The experiment was performed as described in the legend of Table IV, except that all recipient mice 
were sensitized to DNFB by epicutaneous application of 0.5% DNFB (25 #1 per application) on days 
0 and 1. Untreated I-LNC(Ox), or cells treated with 20 I~M reserpine for 1 h [I-LNC(Ox)-Res], were 
injected intradermally into the ears on day 4.  The ears were challenged with  20 #1 of either Ox 
(0.2%), DNFB (0.2%), or vehicle within 1 h of cell injection. The magnitude of the CS reactions was 
determined 24 h later. NS, not significant (P >  0.05). 
to exclude  trypan  blue,  but  virtually eliminated  their  ability to orchestrate  a  CS 
response  in  vivo  (Table  III).  This  result  indicates  that  reserpine  can  block 
expression  of CS even  under  circumstances  which  eliminate  the need  for migra- 
tion of sensitized T  cells to the site of antigen  challenge. 
We  next  performed  an experiment  similar to that  shown  in Table  III, except 
that  the recipient  mice were  first actively sensitized  to  DNFB.  We  then  injected 
reserpine-treated  or  untreated  I-LNC(Ox)  directly  into  the  ears  of these  mice, 
and  challenged  some  ears  with  Ox  and  some  with  DNFB.  The  results  of  this 
experiment  are  shown  in  Table  III.  Reserpine-treated  I-LNC(Ox)  exhibited 
normal  viability by trypan  blue exclusion  and  by cell counts,  but  were  unable  to 
transfer  a  significant  CS  response  after  intradermal  injection  (compare  values 1946  RESERPINE-INDUCED  INHIBITION  OF  CONTACT  SENSITIVITY 
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FIGURE 5.  Reserpine does not induce suppressor activity in the treated I-LNC population. 
In this cotransfer experiment, mice received either 5.0 x 107 I-LNC(Ox) (group A), 5.0 x 107 
I-LNC(Ox) treated with reserpine (20 #M) for 1 h in vitro (group B), or a mixture of 5.0 x 
107 reserpine-treated I-LNC(Ox)  and 5.0 x 107 untreated I-LNC(Ox)  (group C). (*) Reserpine, 
12.5 pg per 5 X 106 cells/ml, for 1 h. All mice were challenged on the left ear with antigen 
(Ox) and on the right (control) ear with vehicle, within 1 h of cell transfer. The CS responses 
were measured 24 h later. Mice that received only I-LNC(Ox) treated with reserpine (group 
B) developed reactions that were much weaker than those in mice that received only untreated 
I-LNC(Ox) (group A). By contrast, CS reactions in mice that received a mixture of the treated 
and untreated cells (group C) were statistically indistinguishable from the reactions in animals 
which received only untreated cells (group A). 
for Ox-challenged left ears in groups A-C, Table IV). By contrast, the presence 
of reserpine-treated I-LNC(Ox) had no significant effect on the development of 
CS reactions to DNFB (compare values for right ears challenged with  DNFB). 
This experiment,  like that  in  Table  III,  showed  that  reserpine-treated  I-LNC 
were  unable  to  orchestrate  a  CS  response  even  when  the  treated  cells  were 
directly injected into the site of antigen challenge. 
The experiment also showed that non-T cell populations required for expres- 
sion of CS (e.g., host accessory cells) were sufficiently active at sites injected with 
reserpine-treated  I-LNC(Ox)  to  support  the  development  of CS  reactions  to 
DNFB.  It is likely that such cells also would have been adequate to collaborate 
with  sensitized  T  cells  in  the  development  of a  CS  reaction  to  Ox.  But  CS 
reactions did not develop at sites injected with reserpine-treated I-LNC(Ox) and 
challenged with Ox. This finding suggests that no matter what effects reserpine 
might  have  on  the  function  of  non-T  cells  in  the  I-LNC  preparations,  the 
consequence  of drug  treatment  which  is  responsible  for reserpine's  ability  to 
block CS is an effect on T  cells. 
Reserpine-induced Inhibition of  Transfer of  CS Is Not Due to Activation of  Suppressor 
Cells.  Epicutaneous  sensitization  of mice  induces  at  least  two  distinct  T  cell 
subpopulations (27, 28): effector T  cells of the CS reaction (TDH) and auxiliary 
suppressor T  cells (Ts,°x). The latter population is required for suppression  of 
the  efferent limb of CS  by suppressor  T  cells (Tserf [28]).  Because the  I-LNC 
populations we transferred would be expected to contain both TDH and  Ts  .... 
we considered the possibility that inhibition of transfer of immunity by reserpine 
reflected an  ability of the drug  to  induce expression of suppressor activity by 
Ysaux. 
We evaluated this possibility with a  cotransfer experiment.  I-LNC were pre- 
pared as described above and part of the population was treated with reserpine 
(12.5 pg per 5  ×  10 6 cells/ml), whereas the rest of the cells were incubated for a 
similar period (1 h) without the drug. As shown in Fig. 5, naive mice that received MEKORI ET  AL.  1947 
5 X 107 untreated I-LNC(Ox) (group A) developed CS responses when challenged 
with the antigen. By contrast, mice that received the same number of I-LNC(Ox) 
treated with reserpine (group B, Fig. 5) developed little or no CS reactions. The 
last group of mice (group C) received a  mixture  (1:1) of reserpine-treated  and 
untreated  I-LNC(Ox)  (a  total  of  1.0  x  108  cells  per  recipient).  These  mice 
developed 24-h CS responses that were statistically indistinguishable  from those 
in mice which received only untreated  I-LNC(Ox). This finding argues against 
the participation of reserpine-activated suppressor cells (with or without specific- 
ity  for  antigen)  in  this  system.  Moreover,  it  also  reinforces  the  notion  that 
reserpine-induced suppression of the transfer of CS is specific for the treated I- 
LNC, and  does not reflect a  systemic effect of the small  amount  of reserpine 
transferred to the recipients with the treated cells. 
We also investigated the role of suppressor cell activation in reserpine-induced 
inhibition  of CS using a  different approach.  Cyclophosphamide selectively de- 
pletes suppressor cell precursors (29) and specifically eliminates the suppressive 
effect induced  by Tsaux (28).  We found that  pretreatment  of mice with cycio- 
phosphamide (200 mg/kg [28]) 2 d before active sensitization had no detectable 
effect on the abrogation of the CS responses induced by reserpine (5 mg/kg, i.p.) 
given  either  6  or  18  h  before challenge  (data  not shown).  Together  with  the 
results of the cotransfer experiment discussed above, these findings suggest that 
activation of suppressor T cells is unlikely to be the mechanism by which reserpine 
inhibits the expression of CS. 
Washing of Reserpine-treated I-LNC Restores Their Ability to Transfer  CS.  We 
next determined whether the reserpine's effect on the transfer of CS with I-LNC 
was reversible. For these studies, we used a modification of an approach described 
by Moorhead (30). I-LNC were treated with reserpine in vitro for 1 h as described 
above (12.5 tzg/5  ×  106 cells/ml).  Some of the treated cells were then  concen- 
trated by centrifugation, resuspended in fresh medium, and immediately injected 
intravenously into syngeneic recipients. The remaining reserpine-treated I-LNC 
were resuspended in RPMI medium containing 5% FCS, but no reserpine, for a 
1 h  incubation  at 37°C.  These cells were then washed twice in  RPMI medium 
with 5% FCS (150 g,  10 min, room temperature), resuspended in RPMI medium 
and  injected  intravenously  into  recipients.  Control  I-LNC  not  treated  with 
reserpine  were  handled  the  same  way  (half the  cells  transferred  after  a  1-h 
incubation at  37°C,  half the cells given an additional  1 h  incubation in RPMI/ 
5% FCS and then two washes). All recipients were ear challenged within  1 h of 
cell transfer and the CS responses were measured 24 h later. 
The  results  are  shown  in  Fig.  6.  As  expected,  mice  that  received  I-LNC 
immediately after the cells had been treated with reserpine  for  1 h  developed 
little or no CS response to antigenic challenge: they exhibited 79% suppression 
of CS by ear swelling measurements, and 92% suppression of CS by 125I-IUDR 
ratios compared with I-LNC transferred  after a  similar  incubation without the 
drug (Fig. 6, group A vs. B). By contrast, mice that received reserpine-treated I- 
LNC  that  were incubated  for an  additional  hour  without  the  drug  and  then 
washed (group D) exhibited CS responses that were statistically indistinguishable 
from those observed in mice which received washed (group C) control cells. This 1948  RESERPINE-INDUCED  INHIBITION OF  CONTACT SENSITIVITY 
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FIGURE 6.  The inhibition of transfer of CS  by reserpine is reversible  by washing of the 
treated cells. Some  mice received  I-LNC(Ox)  that had been incubated with (group B) or 
without (group A) 20/*M reserpine for 1 h in vitro, and which then had been concentrated by 
centrifugation, resuspended in fresh medium, and injected. Other mice received I-LNC(Ox) 
that had been incubated with (group D) or without (group C) 20 #M reserpine for 1 h, but 
which then had been incubated without  reserpine for an additional hour and washed twice 
before injection. (*) Reserpine,  12.5 ug per 5 x  l0  s cells/ml for 1 h. All mice were challenged 
on the left ear with antigen (Ox) and on the right (control) ear with vehicle within 1 h of cell 
transfer.  The CS responses were measured  24 h later.  Reserpine profoundly diminished the 
ability of I-LNC(Ox) to transfer CS if the treated .cells were resuspended  in fresh medium for 
injection immediately after incubation with the drug (compare groups A and B). By contrast, 
I-LNC(Ox) treated with the same amount of reserpine but washed before injection transferred 
CS reactions  whose intensity was statistically indistinguishable from that of CS responses in 
recipients of washed I-LNC(Ox) that had not been exposed to the drug (compare groups C 
and D). 
TABLE  V 
Reserpine Treatment Blocks Transfer of Contact Sensitivity Even When Antigen Challenge Is Delayed 
Until 4 h After Injection of I-LNC 
Cells 
Contact sensitivity responses 
Time of 
Ox thai-  Left ear  Ear t2Sl- 
Ear weight 
lenge  swelling (A X  P  ratio (L/R)  P  IUDR ratio 
10  -4 inches)  (L/R) 
h 
A.  I-LNC(Ox)  1 h  54 ±  2  1.59 4- 0.05  3.54 ±  0.19 
B.  1-LNC(Ox)-Res  1 h  16 _  3  <0.001 vs. A  1.12 _+ 0.01  <0.008 vs. A  1.29 ±  0.08  <0.008 vs. A 
C.  I-LNC(Ox)  4h  45-+3  NS(<0.1)vs.A  1.48±0.05  NS(<0.07) vs.A  4.15-+0.34  NSvs. A 
D.  I-LNC(Ox)-Res  4 h  8  -+ 2  <0.001 vs. C,  1.22 ±  0.04  <0.008 vs. C,  1.39 ±  0.14  <0.008 vs. C, 
<0.001 vs, B  <0.008 vs. B  NS vs. B 
I-LNC(Ox) were recovered  from BALB/c mice sensitized to Ox 5 d previously, and were incubated with 
[I-LNC(Ox)-Res] or without [I-LNC(Ox)] reserpine (20 uM) for 1 h at 37 °  C. The cells then were transferred, 
without prior washing, into naive BALB/c recipients. Mice were challenged on the left ear with Ox, and on 
the right (control) ear with vehicle alone, 1 or 4 h after cell transfer.  Mice received FUDR and J~sI-IUDR 
intraperitoneally  within 30 min of Ox challenge, and the magnitude of the CS reactions was determined 24 
h later. NS, not significant (P > 0.05). 
experiment indicates that reserpine-induced abrogation of the ability of I-LNC 
to transfer CS is reversible. 
We also tested whether reversibility of the drug effect might be demonstrated 
simply by delaying antigenic challenge of mice that  received reserpine-treated 
and unwashed I-LNC. The results of this experiment, shown in Table V, indicate 
that  reserpine treatment of I-LNC  largely blocked the ability of these  cells to 
transfer  CS  even  when  antigenic challenge  was  delayed  until  4  h  after  cell 
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Discussion 
We found that reserpine inhibited at least two of the three T  cell populations 
activated during  sensitization  for  contact  sensitivity.  Reserpine profoundly in- 
hibited the T  cells (Tprolif [26, 27]) which proliferate in vitro when restimulated 
with  the antigen  used for epicutaneous sensitization.  Reserpine also markedly 
interfered with the transfer of contact sensitivity responsiveness to naive synge- 
neic recipients by immune lymph node cells (I-LNC). 
The latter finding suggested that the drug inhibited the activity of the T  cell 
population  capable  of conferring  reactivity  for  delayed  hypersensitivity  (TDH 
[27]).  But  reserpine  can  exert  antiinflammatory  effects  independently  of its 
actions on T  cells. It blocks expression of passive cutaneous anaphylaxis, probably 
by its ability to deplete mast cells of 5-HT (4).  It also inhibits the tissue swelling 
and leukocyte emigration associated with immunologically nonspecific reactions 
to contactants (3, 12), effects observed even in mice lacking mast cell- or platelet- 
derived 5-HT (12). In the present experiments, we were concerned that some of 
the suppression  of CS observed in mice that  received reserpine-treated  I-LNC 
may  have  been  due  to  T  cell-independent  antiinflammatory  actions  of the 
reserpine  transferred  with the  treated  cells.  We therefore attempted  to prove 
that the important effects of the drug in our experiments were due to its actions 
on the adoptively transferred  I-LNC, rather than to systemic or local effects on 
mediators or cellular circuits in the recipient animals. 
First, we considered the hypothesis that reserpine blocks the expression of CS 
and  other  T  cell-mediated  immune  responses  by depleting  mast  cells  of the 
vasoactive amine  serotonin  5-HT (4,  5, 9,  16). The results of our experiments 
indicate that this is a  most unlikely explanation  of reserpine's effect in CS. The 
I-LNC preparations used in our studies contained <0.1% mast cells according to 
staining  with  toluidine  blue  or  Wright's  stain  and  they  contained  only  small 
amounts of 5-HT or histamine.  Moreover, I-LNC from mast cell-deficient W] 
W v mice,  cell preparations  that  contained  no  detectable mature  mast  cells,  5- 
HT, or histamine,  responded to treatment  with reserpine in vitro in a  manner 
indistinguishable from that of I-LNC derived from their normal (+/+) littermate 
controls.  Thus,  reserpine  markedly  inhibited  both  baseline  and  antigen-aug- 
mented incorporation  of [3H]TdR by I-LNC  derived from either  W/W  v mast 
cell-deficient  or  iittermate  control  (+/+)  mice.  Furthermore,  I-LNC  derived 
from  W/W  v mice  and  exposed to  20  #M  reserpine  for  1 h  in  vitro  failed  to 
transfer CS reactivity to naive W/W" mice. By contrast, aliquots of the identical 
preparation  of  I-LNC  that  had  not  been  treated  with  reserpine  were  fully 
competent  to  transfer  CS  to  native  W/W  v mice.  We  feel  that  these  findings, 
together with the observation that systemic administration  of reserpine inhibits 
DH responses in W/W  v mast cell-deficient mice (12,  16), indicate that reserpine 
can block expression of CS independently of an effect on mast cells. 
We then showed that the inhibition  of CS responsiveness was specific for the 
treated I-LNC.  First, animals that received both reserpine-treated  I-LNC from 
mice sensitized to Ox [I-LNC(Ox)] and I-LNC from mice sensitized with DNFB 
[I-LNC(DNFB)]  expressed  little  or  no  CS  to  Ox  challenge,  but  responded 
normally to challenge with DNFB on the opposite ear.  Second, we showed that 
the local intradermal injection of reserpine-treated I-LNC(Ox) did not detectably 1950  RESERPINE-INDUCED  INHIBITION  OF  CONTACT  SENSITIVITY 
interfere  with  the development  of CS to  DNFB at  the same site.  By contrast, 
ears injected  with  reserpine-treated  I-LNC(Ox) did not develop detectable CS 
reactions  after challenge  with  Ox,  a  result  that  also  indicates  that  reserpine's 
ability to block expression of CS cannot be explained simply by an effect of the 
drug on T  cell migration  to the site of antigen challenge.  Finally, we tested the 
effect of transferring reserpine-treated I-LNC(Ox) together with I-LNC(Ox) not 
treated with the drug.  Mice that received a  1:1 mixture of the reserpine-treated 
and the untreated cells responded to antigen challenge in a manner indistinguish- 
able from  that  of mice that  received untreated  I-LNC(Ox) alone.  By contrast, 
mice that received only reserpine-treated cells developed little or no CS response. 
This  confirms  our  I-LNC(Ox)  and  I-LNC(DNFB)  cotransfer  experiment  in 
demonstrating  no systemic effect of the  reserpine  transferred  with the treated 
cells.  It also suggests that  the reserpine treatment  of I-LNC did not induce or 
augment suppressor cell activity in the treated population. 
Two lines of evidence suggest that the drug did not have a cytolytic effect on 
the  treated  cells.  First,  reserpine  had  no  effect on  the  viability of I-LNC,  as 
judged by cell counts and by examining the ability of these cells to exclude trypan 
blue. Second, the effect of the drug on TDH function in vivo was fully reversible. 
Washing  of reserpine-treated  I-LNC  was  required  to  restore  their  ability  to 
transfer CS; simply transferring  the treated I-LNC into naive mice, a maneuver 
that resulted in a dilution of the small amount of drug injected with the treated 
cells, did not have the same effect. It may be of interest that a similar distinction 
between the consequences of washing cells in  vitro and  injecting  them  in  vivo 
has been reported for the inhibitory effect of specific hapten on transfer of CS 
by I-LNC (30). But further work will be required to determine whether there is 
any  relationship  between  the  mechanisms  responsible  for  the  reversibility  of 
reserpine-induced, as opposed to hapten-induced,  inhibition of I-LNC function. 
We do not know the precise mechanism  by which reserpine interferes with I- 
LNC activity.  Although  a  direct  effect on  T  ceils appears  likely,  studies  with 
cloned effector T  cells will be required  to rule out an  indirect effect mediated 
by other elements in the I-LNC preparations.  It will also be of interest to define 
exactly which  manifestations  of T  cell function  are affected by reserpine,  and 
which of these are critical for the expression of CS in vivo. The transfer of CS 
and other DH responses requires that the sensitized T  cells perform a comp|ex 
functional  program,  which  includes  migration  to  sites  of antigen  challenge, 
recognition  of specific  antigen  presented  in  an  immunologically  appropriate 
context, and elaboration of mediators, not yet fully characterized, which amplify 
and  focus  the  inflammatory  response.  Many  of  these  activities  require  the 
collaboration  of host cells (e.g.,  vascular endothelial  cells,  antigen-presenting/ 
processing cells, and leukocytes without immunological specificity). It is possible 
that  reserpine has more than  one effect on T  cell function, and may influence 
some critical non-T cell functions as well. Put differently, nothing we have done 
rules out the possibility that reserpine can interfere with cell-mediated immunity 
through  redundant  effects on multiple cells involved in the reaction.  Neverthe- 
less,  our  cotransfer  experiments  showed  that  reserpine's  ability  to  block  CS 
cannot easily be explained by systemic or local effects of the drug on non-T cell 
populations of the host.  By contrast,  our work strongly suggests that reserpine MEKORI  ET  AL.  1951 
has effects on sensitized T  cells which are sufficient to account for the drug's 
ability to block cell-mediated immune responses. 
Summary 
It has been suggested that reserpine blocks expression of delayed hypersensi- 
tivity (DH) by depleting tissue mast cells of serotonin (5-HT), thereby preventing 
a T  cell-dependent release of mast cell 5-HT necessary to localize and to amplify 
the  DH  response.  However, reserpine  blocks expression of DH  in mast cell- 
deficient mice.  We  therefore decided to  reevaluate the  mechanism by which 
reserpine abrogates expression of cellular immunity, and investigated whether 
the drug might interfere with T  cell activity in vitro or in vivo. At concentrations 
as low as 4 #M, reserpine profoundly suppressed baseline or antigen-augmented 
levels  of [~H]thymidine incorporation by  immune lymph node cells  obtained 
from mice sensitized to the contactant oxazolone [I-LNC(Ox)]. This effect was 
observed both with I-LNC derived from normal mice and with I-LNC derived 
from congenitally mast cell-deficient W/W  v mice, cell preparations that lacked 
detectable mast cells, histamine, and 5-HT. 
Furthermore, treatment of I-LNC with reserpine  (20  t~M) for  1 h  in  vitro 
virtually abolished the ability of these cells to transfer CS to naive mice. This 
was not a cytolytic effect, as the viability of the I-LNC treated with reserpine was 
not affected, and washing of the reserpine-treated I-LNC before transfer fully 
restored their ability to orchestrate a  CS response. The action of the drug was 
not mediated by an effect on mast cells, since the experiment could be performed 
using mast ceil-deficient W/W  v mice as both donors and recipients of I-LNC. In 
addition, the effect was specific for the treated cells: mice that received reserpine- 
treated I-LNC(Ox) intravenously together with untreated I-LNC(DNFB) did not 
develop  CS  to  Ox  but  responded  normally to  DNFB;  and  local  intradermal 
injection of reserpine-treated I-LNC(Ox), which failed to transfer reactivity to 
Ox, did not interfere with the development of CS to DNFB at the same site. 
Finally, cotransfer experiments  indicated that  the  effect of reserpine  on  the 
transfer of CS was not due to activation of suppressor cells. Our findings strongly 
suggest that whatever effects reserpine might have on immunologically nonspe- 
cific host cells, the drug's effects on sensitized T  cells are sufficient to explain its 
ability to block cell-mediated immune responses in vivo. 
Received  for publication 28 May 1985 and in revised  form 27 August  1985. 
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